Who’s earning the big money?


money profit income revenue

New list reveals the world’s top 25 pharma companies by market capitalisation

A new report from Global Data has revealed the 25 leading global pharmaceutical manufacturers in order of their rate of market capitalisation.

The list is:

  1. Johnson & Johnson
  2. Pfizer
  3. Roche
  4. Novartis
  5. Merck US
  6. Abbvie
  7. Amgen
  8. Novo Nordisk
  9. Abbott
  10. Bayer
  11. GSK
  12. Sanofi
  13. Eli Lilly
  14. Gilead
  15. Bristol-Myers Squibb (BMS)
  16. AstraZeneca
  17.  CSL
  18. Biogen
  19. Celgene
  20. Allergan
  21. Shire
  22. Vertex Pharmaceuticals
  23. Merck (Merck KGaA)
  24. Jiangsu Hengrui Medicine
  25. Regeneron

J&J maintained its No.1 position in the Top 25 with Chinese pharmaceutical company, Jiangsu Hengrui Medicine, entering the list during the period, according to Global Data, a leading business data and analytics provider.

The market capitalisation (Mcap) of the top 25 companies collectively reached around $2.7 trillion, the report revealed.

This grew marginally at 1.1% in the second quarter of 2018, with leading companies Merck US, Bayer, GSK, Eli Lilly, CSL and Shire achieving double digit Mcap growth during the same period.

Six of the top 25 companies experienced positive Mcap growth in Q2 2018, with CSL, Shire and Bayer achieving double digit growth rates of 24%, 20% and 16%, respectively.

The Mcap of BMS and Celgene declined over 10% in Q2 2018.

There were plenty of new developments and market activity during Q2 2018, reflecting a growing trend among the big pharma companies to focus on their core business areas, Global Data said.

The moves it highlighted were:

  • BMS announcing its intention to sell its French consumer health business,
  • P&G acquiring Merck KGaA’s vitamin brands;
  • GSK buying a consumer healthcare joint venture from Novartis for $13bn, and;
  • Pfizer announcing plans to divest its European generic-drug business.

The data was collected from global stock exchange latest share price and market cap valuations together with end of year numbers from the companies own latest annual reports, Global Data said.

Click here for more on this report 

Previous Pill testing needs to be considered: experts
Next Working conditions better in GP surgeries?

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.